On Wednesday, Endo International’s Par Pharmaceutical Inc failed to persuade an appeals court in the US to revive its lawsuit seeking to block Eagle Pharmaceuticals Inc from selling Vasostrict — a generic version of Par’s blood-pressure drug, Vasostrict, which is one of the company’s best-selling drugs.
Vasostrict is used to treat patients suffering from critically low blood pressure. Last year, Endo sold more than $900 million worth of the drug.
The US Court of Appeals for the Federal Circuit upheld the decision by a Delaware federal court that Eagle’s generic would not infringe patents owned by Par.
Speaking to Reuters, Eagle’s executive vice president and general counsel, Ryan Debski, said the firm was “very pleased” with the court’s ruling, calling it “thorough and complete.”